Molecular markers in prostate cancer: The role in preoperative staging

Clinical Prostate Cancer

Volumn 1, Issue 1, 2002, Pages 42-50

  Moull, Judd W ^a,b   Merseburger, Axel S ^b   Srivastava, Shiv ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Bcl 2; E Cadherin; Ki 67; Microvessel density; Molecular staging; P27; P53; Prognosis; Prostate specific antigen; Radical prostatectomy; RT PCR

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; UVOMORULIN;

BONE MARROW; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; GENE EXPRESSION; HUMAN; MALE; NEEDLE BIOPSY; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 0011864071     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/cgc.2002.n.006     Document Type: Review

References (82)

1. Moul JW. Treatment options for prostate cancer: Part I-staged, grade, PSA, and changed in the 1990s. Am J Managed Care 1998; 4:1031-1036.
2. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15:331-335.
3. Ferguson JK, Oesterling JE. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol Clin North Am 1994; 21:677-685.
4. Russell KJ, Dunatov C, Hafermann MD, et al. Prostare specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991; 146:1046-1052.
5. Schellhammer PF, el-Mahdi AM, Wright GL Jr, et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 1993; 42:13-20.
6. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A 1988; 85:5698-5702.
7. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52:6110-6112.
8. Katz AE, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43:765-775.
9. Katz AE, de Vries GM, Begg MD, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75:1642-1648.
10. Olsson CA, de Vries GM, Raffo AJ, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996; 155:1557-1562.
11. Katz AE, De Vries GM, Olsson CA, et al. Molecular staging of genitourinary malignancies. Urology 1996; 47:948-958.
12. Thiounn N, Saporta F, Flam TA, et al. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 1997; 50:245-250.
13. Sokoloff MH, Tso CL, Kaboo R, et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996; 156:1560-1566.
14. Sardi I, Piazzini M, Ponchietti R, et al. The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma. J Mol Med 1997; 75:751-757.
15. Melchior SW, Corey E, Ellis WJ, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3:249-256.
16. Ignatoff JM, Oefelein MG, Watkin W, et al. Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 1997; 158:1870-1875.
17. Henke W, Jung M, Jung K, et al. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 1997; 70:52-56.
18. de Cremotux P, Ravery V, Podgorniak MP, et al. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol 1997; 32:69-74.
19. Ghossein RA, Rosai J, Scher HI, et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997; 50:100-105.
20. Ghossein RA, Scher HI, Gerald WL, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13:1195-1200.
21. Gao C, Ali A, Rawal SK, et al. Diagnostic potential of circulating prostatic epithelial cells in prostate cancer detection. Proc Am Assoc Cancer Res 2002; 43:Abstract #1941.
22. Llanes L, Paez A, Ferruelo A, et al. Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging. BJU Int 2000; 86:1023-1027.
23. Mejean A, Vona G, Nalpas B, et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 2000; 163:2022-2029.
24. Wood DP Jr, Banks ER, Humphreys S, et al. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74:2533-2540.
25. Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997; 15:3451-3457.
26. Gao CL, Dean RC, Pinto A, et al. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 1999; 161:1070-1076.
27. Daja MM, Aghmesheh M, Ow KT, et al. Beta-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer? Mol Urol 2000; 4:421-427.
28. Zippelius A, Kufer P, Honold G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15:2701-2708.
29. Leissner S, Steinbach F, Brenner W, et al. Immunozytologische farbung des knochenmarks bei patienten mit scheinbar organbegrenzten tumoren: Nachweismoglichkeit einer beginnenden tumordisseminierung? Akt Urol 1995; 26.
30. Kollermann J, Heseding B, Helpap B, et al. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int J Cancer 1999; 84:145-149.
31. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162:2040-2045.
32. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-915.
33. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
34. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-456.
35. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-849.
36. Voeller HJ, Sugars LY, Pretlow T, et al. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994; 151:492-495.
37. Van Veldhuizen PJ, Sadasivan R, Garcia F, et al. Mutant p53 expression in prostate carcinoma. Prostate 1993; 22:23-30.
38. Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147:92-101.
39. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60:1585-1594.
40. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156:1511-1516.
41. Theodorescu D, Broder SR, Boyd JC, et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158:131-137.
42. Leibovich BC, Cheng L, Weaver AL, et al. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 2000; 163:1756-1760.
43. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000; 164:716-721.
44. Ruijter E, van de Kaa C, Aalders T, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11:276-281.
45. Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161:1238-1243.
46. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89:158-165.
47. Huang A, Gandour-Edwards R, Rosenthal SA, et al. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998; 51:346-351.
48. Matsushima H, Kitamura T, Goto T, et al. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 1997; 158:2278-2283.
49. Scherr DS, Vaughan ED Jr, Wei J, et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999; 162:12-17.
50. Sentman CL, Shutter JR, Hockenbery D, et al. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67:879-888.
51. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41:899-906.
52. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52:6940-6944.
53. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143:390-400.
54. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998; 110:443-449.
55. Johnson MI, Robinson MC, Marsh C, et al. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 1998; 37:223-229.
56. Bylund A, Stattin P, Widmark A, et al. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol 1998; 49:143-148.
57. Bauer JJ, Connelly RR, Sesterhenn IA, et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997; 79:952-962.
58. Bettencourt MC, Bauer JJ, Sesterhenn LA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156:1064-1068.
59. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29:949-954.
60. Matsuura H, Hayashi N, Kawamura J, et al. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation. Eur Urol 2000; 37:212-217.
61. Mucci NR, Rubin MA, Strawderman MS, et al. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 2000; 92:1941-1942.
62. Scalzo DA, Kallakury BV, Gaddipati RV, et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol 1998; 109:163-168.
63. Dunsmuir WD, Gillett CE, Meyer LC, et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000; 86:869-878.
64. Brawer MK, Deering RE, Brown M, et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73:678-687.
65. Rogatsch H, Hittmair A, Reissigl A, et al. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997; 182:205-210.
66. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79:772-779.
67. Strohmeyer D, Rossing C, Strauss F, et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42:26-33.
68. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160:459-465.
69. Rubin MA, Buyyounouski M, Bagiella E, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999; 53:542-547.
70. Borre M, Offersen BV, Nerstrom B, et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78:940-944.
71. Kuczyk M, Machtens S, Hradil K, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 1999; 81:1052-1058.
72. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-945.
73. Erdamar S, Yang G, Harper JW, et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999; 12:751-755.
74. Thomas GV, Schrage MI, Rosenfelt L, et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 2000; 164:1987-1991.
75. Douglas TH, Moul JW. Applications of neural networks in urologic oncology. Semin Urol Oncol 1998; 16:35-39.
76. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999; 91:1758-1764.
77. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60:1677-1682.
78. Carlisle AJ, Prabhu VV, Elkahloun A, et al. Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol Carcinog 2000; 28:12-22.
79. Luo J, Duggan DJ, Chen Y et al. Human prostate cancer and benign prostate hyperplasia. Cancer Res 2001; 61:4683-4688.
80. Dhanasekaran SM, Barette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822-826.
81. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-847.
82. Moch H, Kononen T, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001; 8:14-20.